Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies

European Journal of Internal Medicine

Volumn 26, Issue 4, 2015, Pages 285-291

  Ungprasert, Patompong ^a,b   Cheungpasitporn, Wisit ^a   Crowson, Cynthia S ^a   Matteson, Eric L ^a  

^a MAYO CLINIC   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Epidemiology; Meta analysis; NSAIDs; Renal; Systematic review

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC;

ACUTE KIDNEY FAILURE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; HAZARD RATIO; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; RISK ASSESSMENT; RISK FACTOR; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; CLASSIFICATION; ODDS RATIO;

ACUTE KIDNEY INJURY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; RISK FACTORS;

EID: 84928828043     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.03.008     Document Type: Article

References (34)

1. G.C. Curhan, A.J. Bullock, S.E. Hankinson, W.C. Willett, F.E. Speizer, and M.J. Stampfer Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women Pharmacoepidemiol Drug Saf 11 2002 687 693
2. S. Harirforoosh, W. Asghar, and F. Jamali Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications J Pharm Sci 16 2013 821 847
3. P. Ungprasert, W. Kittanamongkolchai, C. Price, S. Ratanapo, N. Leeaphorn, D. Chongnarungsin, et al. What is the "safest" non-steroidal anti-inflammatory drugs? Am Med J 3 2012 115 123
4. M. Mamdani, P.A. Rochon, D.N. Juurlink, A. Kopp, G.M. Anderson, and G. Naglie Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs BMJ 325 2002 624
5. F. McKenna, D. Borenstein, H. Wendt, C. Wallemark, J.B. Lefkowith, and G.S. Geis Celecoxib versus diclofenac in the management of osteoarthritis of the knee Scand J Rheumatol 30 2001 11 18
6. W.G. Bensen, S.Z. Zhao, T.A. Burke, R.A. Zabinski, R.W. Mukach, C.J. Maurath, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo J Rheumatol 27 2000 1876 1883
7. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 Sep 13 1247 1255
8. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
9. P. McGettigan, and D. Henry Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 2006 1633 1644
10. K. Beard, D.H. Lawson, and G.J. MacFarlane Non-steroidal anti-inflammatory drugs and acute renal disease: a case control study Pharmacoepidemiol Drug Saf 1 1992 3 9
11. J.M. Evans, E. McGregor, A.D. McMahon, M.M. McGilchrist, M.C. Jones, G. White, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure QJM 88 1995 551 557
12. C.E. Leonard, C.P. Freeman, C.W. Newcomb, P.P. Reese, M. Herlim, W.B. Bilker, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury Pharmacoepidemiol Drug Saf 21 2012 1155 1172
13. A.D. Furlan, E. Irvin, and C. Bombardier Limited search strategies were effective in finding relevant nonrandomized studies J Clin Epidemiol 59 2006 1303 1311
14. A. Stang Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses Eur J Epidemiol 25 2010 603 605
15. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
16. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
17. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trial J Clin Epidemiol 50 1997 683 691
18. S. Pérez Gutthann, L.A. García Rodríguez, D.S. Raiford, A. Duque Oliart, and J. Ris Romeu Non-steroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure Arch Intern Med 156 1996 2433 2439
19. M.R. Griffin, A. Yared, and W.A. Ray Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons Am J Epidemiol 151 2000 488 496
20. C. Huerta, J. Castellsague, C. Varas-Lorenzo, and L.A. Garcia Rodriguez Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population Am J Kidney Dis 45 2005 531 539
21. V. Schneider, L.E. Levesque, B. Zhang, T. Hutchinson, and J.M. Brophy Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis Am J Epidemiol 164 2006 881 889
22. J.P. Lafrance, and D.R. Miller Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury Pharmacoepidemiol Drug Saf 18 2009 923 931
23. H.A. Guess, L.M. Strand, N. Helston, E. Lydick, U. Berg-man, and K. Wolski Hospitalizations for renal impairment among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan, Canada, 1983 K.D. Rainsford, G.P. Velo, editors. Side-effects of anti-inflammatory drugs, part 2 1985 MTP Lancaster, UK 367 374
24. J.A. Oates, G.A. FitzGerald, R.A. Branch, E.K. Jackson, H.R. Knapp, and L.J. Roberts II Clinical implications of prostaglandin and thromboxane A2 formation N Engl J Med 319 1988 689 698
25. D.M. Clive, and J.S. Stoff Renal syndromes associated with nonsteroidal antiinflammatory drugs N Engl J Med 310 1984 563 572
26. A. Whelton Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications Am J Med 106 1999 13S 24S
27. J. Zhang, E.L. Ding, and Y. Song Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials JAMA 296 2006 1619 1632
28. P. Rao, and E.E. Knaus Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond J Pharm Pharm Sci 11 2008 81s 110s
29. J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, and J.R. Vane Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc Natl Acad Sci U S A 90 1993 11693 11697
30. S.R. Ahmad, C. Kortepeter, A. Brinker, M. Chen, and J. Beitz Renal failure associated with the use of celecoxib and rofecoxib Drug Saf 25 2002 537 544
31. A. Whelton, R.L. Stout, P.S. Spilman, and D.K. Klassen Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison Ann Intern Med 112 1990 568 576
32. M. Etminan, and A. Samii Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs Pharmacotherapy 24 2004 964 969
33. L.B. Signorello, J.K. McLaughlin, L. Lipworth, S. Friis, H.T. Sørensen, and W.J. Blot Confounding by indication in epidemiologic studies of commonly used analgesics Am J Ther 9 2002 199 205
34. K. Gooch, B.F. Culleton, B.J. Manns, J. Zhang, H. Alfonso, M. Tonelli, et al. NSAID use and progression of chronic kidney disease Am J Med 120 2007 e1 e7